Abbott Laboratories
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $10,635,000 | $10,377,000 | $9,964,000 | $10,241,000 |
Gross Profit | 5,937,000 | 5,807,000 | 5,544,000 | 5,258,000 |
EBITDA | 2,907,000 | 2,638,000 | 2,340,000 | 2,870,000 |
EBIT | 2,106,000 | 1,833,000 | 1,535,000 | 2,057,000 |
Net Income | 1,646,000 | 1,302,000 | 1,225,000 | 1,594,000 |
Net Change In Cash | 10,635,000 | 10,377,000 | 9,964,000 | 10,241,000 |
Free Cash Flow | 2,149,000 | 1,427,000 | 627,000 | 2,283,000 |
Cash | 7,558,000 | 6,987,000 | 6,284,000 | 6,896,000 |
Basic Shares | 1,748,000 | 1,751,000 | 1,750,000 | 1,748,000 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $40,109,000 | $43,653,000 | $43,075,000 | $34,608,000 |
Gross Profit | 22,134,000 | 24,511,000 | 24,538,000 | 19,605,000 |
EBITDA | 10,605,000 | 12,380,000 | 12,742,000 | 8,789,000 |
EBIT | 7,362,000 | 9,113,000 | 9,204,000 | 5,462,000 |
Net Income | 5,723,000 | 6,933,000 | 7,071,000 | 4,495,000 |
Net Change In Cash | 40,109,000 | 43,653,000 | 43,075,000 | 34,608,000 |
Cost of Revenue | 205,000 | 3,031,000 | 2,907,000 | |
Free Cash Flow | 5,059,000 | 7,804,000 | 8,648,000 | 5,724,000 |
Cash | 6,896,000 | 9,882,000 | 9,799,000 | 6,838,000 |
Basic Shares | 1,749,000 | 1,764,000 | 1,789,000 | 1,786,000 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | $1.21 |
2024-06-30 | $1.14 |
2024-03-31 | $0.98 |
2023-12-31 | $1.19 |
